Flavivirus infections are a serious healthcare concern in tropical and subtropical countries.
| INTRODUCTION
Febrile diseases are one of the most frequent causes of morbidity and mortality in developing countries. For many years, malaria was the leading cause of fever, especially in children, and contributed to significant mortality in sub-Saharan Africa. However, recent studies highlight the importance of non-malarial causes. Nile virus (in Africa, South Asia, Americas), the Japanese encephalitis virus (in South Asia), the Saint Louis encephalitis virus (in Americas) or the Zika virus that is now emerging in Africa, Asia, and the Americas. 3, 4 Clinical manifestations of these diseases are often asymptomatic or mildly symptomatic with an acute self-limiting febrile syndrome in a few days that includes headache, retro-orbital pains, sometime rash.
However, for arbovirus such as dengue and Zika, a significant percentage of patients develop more severe forms of the disease or complications that imply that these patients must be taken in charge in a specific care environment.
The problem for the clinician is the differential diagnosis of these pathologies to adapt the patients care. For dengue patients, for instance, fast and reliable early diagnosis is essential for the management of clinical cases that may progress to severe dengue.
For Zika, the management of pregnant women is important because of the potential damage by the virus to the fetus brain. This early diagnosis can be accomplished by amplification of the viral genome (RT-PCR), by virus isolation or by looking for specific IgM. Detecting viral Non Structural glycoprotein 1 (NS1) in the blood of patients represents an alternative path in the early diagnosis of flaviviruses. The assay can also be useful for epidemiological surveillance. [5] [6] [7] NS1, a secreted viral glycoprotein produced by infected cells, is synthesized as a monomer and is dimerized rapidly after post-translational modifications in the endoplasmic reticulum. Dimers are transported to the cell surface and associate as hexamers that accumulate in large amounts in the extracellular medium. 8, 9 For most countries affected by arboviruses such as DENV and ZIKV, the price of a regular diagnostic test is often considered to be too expensive. New diagnostic tests should be developed by taking into account the challenges posed by the economy of developing countries. Paper fabrication is one of the most mastered technologies of human history. Currently, paper-based materials are used for numerous biochemical analyses from the dipstick assays for urine analysis to the lateral flow assays (LFAs) for the rapid detection of infectious diseases. 11, 12 Since the basics of Lateral Flow Assays (LFA) have been laid, they have been constantly upgraded. Recently, Whitesides et al. at Harvard University introduced paper-based microfluidics to manufacture low cost and very simple Paper Analytical Devices (PAD). [13] [14] [15] Paper is hydrophilic and porous, thus PADs are mainly based on capillary force to drive aqueous fluid movement into designed channels without mechanical assistance. 16 PADs are made by patterning physical or chemical hydrophobic boundaries to form channels on paper. 17 Due to the compatibility of the paper with a large number of components, PADs can be functionalized by adding chemical or biological molecules that can be immobilized by a physical absorption or a chemical coupling. Finally, paper is biodegradable and easy to recycle. 18, 19 A traditional LFA corresponds to the assembling of different material.
A piece of fiber glass paper is used to separate red blood cells from plasma.
Fiber glass paper is located upstream from the conjugate pad (made of cellulose paper) and the test strip (nitrocellulose membrane). 20 Conversely, in the present study, the analytical device that has been developed consists of a single piece of fiber glass paper. The proof of concept, using this microfluidic device, has been performed using the NS1
proteins of dengue and Zika as target antigens to be detected from plasma and whole blood samples, in simplex and multiplex formats.
| MATERIALS AND METHODS

| Materials and specimens
DENV-and ZIKV-negative plasma and whole blood specimens from healthy donors were obtained from the French National Blood Bank (Etablissement Français du Sang, Lyon, France 
| μPAD manufacturing and functionalization
The pattern was wax-printed on a standard sheet of 80 gr paper (Evercopy, France), and then transferred to MF1 paper (Wattman) by blotting in "sandwich" at 120°C under a pressure of 0.1 bar for 3 min.
At the end of the process, the pattern was blotted on MF1 paper (cf 
| Test of samples on the μPAD
The functionalized μPAD was loaded by 25 μL of sample (plasma or To adjust the reading to the current lighting conditions, the Blank, corresponding to a white non-reactive area of the paper, was measured.
The S signal was finally calculated as S ¼
TestÀBlank
MockÀBlank : Data (μPAD picture, areas measured, and pixel quantification of each area) were saved in the internal memory of the smartphone. The entire process from the sample loading to the signal quantification is illustrated in Fig. 1 .
| Raw material selection for NS1 detection by sandwich-ELISA and application on paper
In order to determine the couple of antibodies that best fitted for the NS1 protein detection for dengue and Zika, different antibodies were successively tested by sandwich-ELISA on microplates either as capture or detection antibodies, when labeled with AP. Western-blots previously conducted on the dengue or Zika NS1 proteins showed that p122 and p82 dengue polyclonal antibodies generated strong cross reactive signal on Zika NS1 protein (data not shown). Consequently, these two antibodies can potentially be used for both dengue and Zika NS1 detection.
As illustrated in Fig. 2A , for dengue, the combination of rabbit polyclonal antibodies for capture associated with the 8C1B2 monoclonal antibody in detection gave the higher OD (mean of OD = 1.801) followed by the 6C6A9 (mean of OD = 1,491). The use of monoclonal antibodies 8C1B2 and 6C6A9 for the NS1 capture associated with polyclonal antibodies for the detection also worked well (mean of OD = 1. 413). For Zika virus (see Fig. 2B ), the polyclonal antibody p122 or p82 as capture antibodies in sandwich with the monoclonal antibody 4A8C12 in detection showed to be the couple of antibodies that led to higher optical density (mean of OD = 1.640).
Because p122 and p82 polyclonal antibodies were not labeled, it was not possible to test the combinations using these two antibodies both in capture and detection.
Thus, the antibody couples selected for the NS1 sandwich ELISA on paper were p122/8C1B2 for dengue and p122 (or p82)/4A8C12, for Zika.
Finally, these combinations were tested on the μPAD by loading 25 μL of sample (whole blood or plasma) containing different quantities of NS1 proteins of different serotypes (serotypes 1, 2, and 3, for dengue). The complete process, from the sample loading to the S calculation, took less than 8 min.
3.2 | Improvement of the signal intensity and decrease of the background noise Two tracks were explored to reduce the signal intensity of the background sometimes observed on the μPAD and to increase the specific signal. 
| Determination of the limit of detection
In order to determine the limit of detection, the mean of the S signal obtained on μPADs loaded with negative samples (without NS1) was calculated. Thirty-five μPADs were loaded with 25 μL of dengue/Zika negative plasma. The S signal was estimated for each μPAD and the mean and the standard deviation were deduced. For the μPAD functionalized with dengue antibodies, the mean (M) of S was 1.12 and the standard deviation (SD) was 0.18. Consequently, a test was considered positive on plasma when the S value was higher than M + 2SD = 1.48. For the μPAD functionalized with Zika antibodies, the mean (M) of S was 1.1 and the standard deviation (SD) was 0.11. The test was considered positive when S was higher than 1.32. In parallel, the S signal was estimated for 35 μPAD loaded with dengue/Zika negative whole blood. For the μPAD functionalized with dengue antibodies, the mean (M) of S was 1.24 and the standard deviation (SD) was 0.14. Consequently, a test was considered positive on whole blood when the S value was higher than M + 2SD = 1.52. For the μPAD functionalized with Zika antibodies, the mean (M) of S was 1.16 and the standard deviation (SD) was 0.15. The test was considered positive when S was higher than 1.46.
Serial dilutions, from 40 μg/mL to 5 ng/mL, of dengue NS1 protein (serotype 1, 2, or 3) in healthy, dengue/Zika negative plasma were tested on the μPAD functionalized with appropriate antibodies. The S signal was calculated by the smartphone application. If S was found to be higher than 1.48, the signal was considered as positive. For dengue serotype 1, 2, and 3, the limit of detection was estimated to be 10 ng/mL (cf Table 1 , NS1-1, NS1-2, and NS1-3). In whole blood, the limit of detection was found to be 20 ng/mL. For Zika NS1, the limit of detection | 1523 in plasma and in whole blood was 10 and 20 ng/mL, respectively. The final result was always obtained in less than 8 min.
Sometimes, S was found aberrant (cf Table 1 , in bold). That corresponded to imperfections ("wrinkles") on the MF1 paper that modified the gray level on the picture and had an impact on the signal calculation. Some attempts to reduce this effect (pressing of the paper, addition of plastic film on the top of the μPAD) were unsuccessful.
As a reference, a commercial dengue Lateral Flow Assay (CTK Biotech) was tested in parallel using the same dilutions of dengue NS1 protein. For the commercial LFA, the limit of detection in plasma or whole blood was estimated to be 20 ng/mL and the final result was obtained in 21-25 min (not shown).
For the Zika NS1 protein, the limit of detection by the μPAD was estimated to be 10 ng/mL (plasma) or 20 ng/mL (blood). Because no commercial in vitro diagnostic LFA was currently available for NS1 Zika detection, no benchmarking was conducted.
In conclusion, the μPAD solution enabled better performances compared to a commercial lateral flow assay (on dengue) both in terms of limit of detection and of time-to-result. The device worked on whole blood an on plasma and was able to detect both Zika and dengue serotype 1, 2, 3 NS1 proteins.
| Test of samples from acute dengue patients on the μPAD
All the data presented in the previous paragraphs were obtained on plasma or blood spiked with recombinant NS1 proteins. To test the μPAD with patients samples and compare the results obtained with a reference method, five plasma samples from acute dengue patients were tested both on μPAD and on a commercial LFA. Plasma samples came from primary acute dengue patients (serotype 1 and 3), taken early during the course of the disease (mean = 4.2 days after the onsets of symptoms). All were previously confirmed to be NS1 positive using the Platelia NS1 ELISA (Biorad). Four out of five plasmas were taken from female patients. Patients were 25-64 years old (mean = 36.8 years).
The results (see Fig. 4A ) showed that all the NS1 positive patients were detected positive by the μPAD. The S values were higher than 1.48, considered as the positivity threshold. Simultaneously, the same plasma specimens were tested with the OneSite Duo Dengue Rapid test (CTK Biotech), as a reference in vitro diagnostic kit. As for the μPAD, all the plasma were found positive (see Fig. 4B ). The signal appeared generally more intense than for the μPAD, except for two samples, P8 (38 year old female taken at day 4 after onsets of symptom; DENV serotype 1) and P35 (a 27 years old female taken at day 4 after onsets; DENV serotype 3) that were barely visible. For the μPAD, P8 and P35 corresponded also to the lowest positive S signal.
In conclusion, it is possible, using the μPAD, to detect the NS1 protein in plasma specimens from acute dengue patients.
| Multiplex detection of dengue and Zika NS1 proteins on plasma
In order to assess the possibility of detecting the dengue or Zika NS1
protein from the same sample on the same μPAD, a new μPAD was designed and assessed. This new μPAD is composed of two channels. In conclusion, it was possible to specifically detect, the Zika and/or dengue NS1 protein in a multiplexed μPAD.
3.6 | Correlation between the smartphone application and reference software using gray level analysis In conclusion, the S values calculated by using the smartphone application internally developed were compatible with the values obtained by using a reference method of gray level quantification.
| DISCUSSION
Paper-based devices provide an alternative technology for simple, cost-effective, portable, and recyclable diagnostic tools for many applications including clinical diagnosis. They are potentially well adapted to low income countries or when health costs are not covered by public health agencies. In the present article the proof of principle of the multiplex detection of flavivirus NS1 proteins in biological sample using a paper-based cost-effective device was established.
Among flaviviruses, dengue, and Zika viruses are two arboviruses transmitted by Aedes mosquitoes that co-circulate in the same geographic areas. 22 During the acute phase of the infection in humans, up to 7 days after the onset, the symptoms between these two viruses are generally quite similar. However, these diseases may evolve to complications requiring a differentiated care and that do not concern the same at-risk populations. Rapid diagnostic tools that enable to differentiate between these viruses during the acute febrile phase would be of great help in endemic countries.
The main advantage of μPAD over conventional laboratory-based tests such as ELISA, in addition to a reduced cost of goods, is that it can be easily manufactured in every part of the world. In addition, the results are quickly provided (here in less than 8 min) and can be read by the naked eye, and without any instrument. However, it is also possible, thanks to a simple smartphone application that we have developed, to perform a quantitative evaluation of the results obtained both on Test and Mock zones and consequently to increase the sensitivity of reading, even by an unskilled user. These data could possibly be transmitted by SMS to a centralized laboratory or hospital, for epidemiological purpose, for instance.
Unlike the traditional LFA that requires assembly of several pads and membranes made of different materials to ensure the sample preparation and analysis (sample pad and absorbent pads made of cellulose, conjugate pad made of glass fiber, and test strip made of nitrocellulose), 20 in the solution presented here only one material is needed to perform all these steps. A simple wax-patterned piece of MF1 paper allows the plasma to be separated from the red blood cells thanks to the glass fiber that is one of the main components of MF1.
Because MF1 is hydrophilic and porous, the migration of the sample to the specific antibodies is driven by capillarity force, without mechanical assistance. The microfluidic pump is ensured by the presence of paper surrounding the wax-printed pattern. The use of a unique material would enable a simplification and, consequently, a reduction in the cost of manufacturing.
The μPAD developed here shows a reduced background level and/or an increased specific signal when a washing step with 10 μL of PBS and a blocking agent on the test zone are added to the workflow.
Furthermore, the use of the smartphone application brings an additional value by automatically subtracting the background from the test signal. However, the background must be reduced further to minimize the false positives that could result from non-specific binding of assay reagents.
To optimize the specific signal, different concentrations of specific antibodies have also been tested. The optimal concentrations corresponded to those previously described in the literature for other paper-based devices. 23, 24 The use of specific monoclonal antibodies for each virus instead of the dengue polyclonal p122 could probably help to reduce the background.
Compared to a commercial dengue LFA, it was possible, by using the μPAD, to improve the limit of detection by two. In addition the time-to-result was reduced approximately threefold.
It was demonstrated that the dengue NS1 can also be detected in acute dengue patient plasma specimens, demonstrating that the μPAD has potential clinical applications.
Previous studies have determined the median level of circulating NS1 in serum for patients infected with DENV. It varied among individuals during the course of the disease, but it was generally around 120 ng/mL of serum, ranging from 10 ng/mL to 50 μg/mL.
25,26
The limit of detection estimated with the solution developed here, is compatible with these biological data.
The functions of DENV NS1 have not yet been fully elucidated but NS1 probably involves in pathogenicity. The diagnosis of DENV acute infection using NS1 LFA has been shown to be a good first-line test for dengue fever. 27 The NS1 antigen was found circulating from the first day after the onset of fever up to day 9, once the clinical phase of the disease is over. The NS1 protein could be detected even when viral RNA was negative in reverse transcriptase-PCR. 25 In a secondary DENV infection, the immune complexes formed by NS1 and antibodies increase rapidly via an anamnestic immune response; thus, the antigen is rarely found at 5-7 days after the onset of symptoms in secondary DENV-infected patients. 28 For Zika NS1, few data are currently available. 29, 30 No commercial in vitro diagnostic kit for NS1 detection is currently marketed. This makes the μPAD benchmarking difficult.
The μPAD can be used for NS1 dengue/NS1 Zika detection in multiplex. In tropical or subtropical countries, such as Brazil, a multiplexed assay might contribute to the management of testing campaigns at the point-of-care settings by minimizing the management of waste and simplifying the workflow in hospitals or dispensaries where many patients would be tested for the main arboviruses. Because transmission of many arboviruses, including flaviviruses, is carried out by the same Aedes mosquitoes, that colonize the same countries, it could also be interesting to include other viruses such as chikungunya and yellow fever to this multiplex. 31, 32 The proof of concept being validated, it would be interesting to test subsequently blood samples from acute patients infected by dengue and/or Zika viruses in order to determine the clinical performances of our solution and compare them with the existing in vitro diagnostic kits.
In the present example, the multiplexed dengue/Zika test could help health workers in the accurate diagnosis and differentiation of Zika and dengue fever, two diseases caused by flaviviruses that are characterized by common symptoms during the acute phase, that colocalize in endemic countries but that require different management on distinct risk populations. 
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